^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Regimen: | (dexamethasone + bortezomib + Xpovio (selinexor)) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/18/2020
Excerpt:
XPOVIO is a nuclear export inhibitor indicated...In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Secondary therapy:
dexamethasone
Source:
Title:
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published date:
02/03/2021
Excerpt:
Recommendations: Patients who receive second-line therapy: Patients who are refractory to lenalidomide upfront could receive either PomVD, DaraKd, IsaKd or DaraVd [I, A]. PomVd is the approved indication with best results, in terms of PFS, as second-line therapy in lenalidomide-refractory patients. DaraKd has given the best reported PFS to date in lenalidomide-refractory patients....Similarly, IsaKd and SVd, which are also suitable for this setting [I, A]...
DOI:
10.1016/j.annonc.2020.11.014
Source:
Title:
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
Published date:
11/14/2020
Excerpt:
Median progression-free survival was 13·93 months (95% CI 11·73–not evaluable) with selinexor, bortezomib, and dexamethasone and 9·46 months (8·11–10·78) with bortezomib and dexamethasone (hazard ratio 0·70 [95% CI 0·53–0·93], p=0·0075)….A once-per-week regimen of selinexor, bortezomib, and dexamethasone is a novel, effective, and convenient treatment option for patients with multiple myeloma.
Secondary therapy:
dexamethasone
DOI:
10.1016/S0140-6736(20)32292-3
Trial ID:
